Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (10)
Type
(
1 selected
)
Type
Guidance (295)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (6)
Medical technologies guidance (7)
Technology appraisal guidance (280)
Apply filters
Showing 141 to 150 of 295
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]
Technology appraisal guidance
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]
Technology appraisal guidance
Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728
Technology appraisal guidance
Mavorixafor for treating WHIM syndrome ID3946
Technology appraisal guidance
Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237]
Technology appraisal guidance
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400
Technology appraisal guidance
Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730
Technology appraisal guidance
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442
Technology appraisal guidance
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over TS ID 11777
Technology appraisal guidance
Previous page
1
…
13
14
Current page
15
16
17
…
30
Page
15
of
30
Next page
Results per page
10
25
50
All
Back to top